GSK's Latozinemab Fails to Meet Clinical Endpoint in FTD-GRN Trial, Alector Announces.

GSK and Alector announced results from the INFRONT-3 clinical trial evaluating latozinemab in frontotemporal dementia caused by a mutation in the progranulin gene. While treatment achieved a significant improvement in a biomarker endpoint, it did not demonstrate clinical benefit in slowing disease progression. Preliminary safety data has not revealed major concerns, but further analysis is ongoing. The open-label extension and continuation study for latozinemab will be discontinued.